Business Information
The group’s principal activities include developing and commercializing therapeutic clinical products. The group products sold under the trade names Flonase(R), Emezine(R) Nasonex(R), Rhinocort Aqua(R), Nasacort AQ(R), and Nasarel(R). The group’s operates through two segments namely biopharmaceutical products and services and, specialty pharmaceuticals. Specific customers of the group include Cardinal Health and McKesson Corporation. The group operates from the United States and Europe. Of the total sales in the year 2006, biopharmaceutical products and services accounted for $17,609,286 and specialty pharmaceuticals $7,448,762.
|
|
Name |
Title
|
Email
|
| Francis O'Donnell | Chmn., CEO | N/A | | Alan Pearce | Dir., CFO | N/A | | Steven Arikian | Dir., Pres., COO - Product Development, Marketing Services | N/A | | David Schubert | Dir. | N/A | | Edmund King | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 25,058 | (43,395) | | 2005 | 25,195 | (44,736) | | 2004 | 25,936 | (23,226)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
